Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients

Seminars in Hematology

Volumn 53, Issue 3, 2016, Pages 216-217

  Peterlin, Pierre ^a   Guillaume, Thierry ^a   Delaunay, Jacques ^a   Mohty, Mohamad ^a,b,c   Garnier, Alice ^a   Mahe, Beatrice ^a   Dubruille, Viviane ^a   Blin, Nicolas ^a   Voldoire, Maud ^a   Touzeau, Cyrille ^a   Chauvin, Cecile ^a   Gastinne, Thomas ^a   Béné, Marie C ^a   Le Gouill, Steven ^a   Moreau, Philippe ^a   Chevallier, Patrice ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE;

ACUTE MYELOBLASTIC LEUKEMIA; DOSE RESPONSE; DRUG EFFICACY; HUMAN; LETTER; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SINGLE DRUG DOSE;

EID: 84991263180     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2016.06.001     Document Type: Letter

References (10)

1. [1] Larson, R.A., Sievers, E.L., Stadtmauer, E.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 (2005), 1442–1452.
2. [2] Chevallier, P., Delaunay, J., Turlure, P., et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 26 (2008), 5192–5197.
3. [3] Castaigne, S., Pautas, C., Terre, C., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379 (2012), 1508–1516.
4. [4] Jones, R.J., Lee, K.S., Beschorner, W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44 (1987), 778–783.
5. [5] Chantepie, S.P., Reboursiere, E., Mear, J.B., et al. Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma, 2015, 1–5.
6. [6] Prebet, T., Etienne, A., Devillier, R., et al. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. Cancer 117 (2011), 974–981.
7. [7] Chevallier, P., Robillard, N., Ayari, S., et al. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. Br J Haematol 143 (2008), 744–746.
8. + AML patient allows to second remission and is feasible without extra toxicity. Leuk Res 32 (2008), 1321–1322.
9. [9] O׳Hear, C., Inaba, H., Pounds, S., et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 119 (2013), 4036–4043.
10. [10] Amadori, S., Suciu, S., Selleslag, D., et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol 149 (2010), 376–382.